STD rates in US reach record high, CDC says

>> Read more trending news 

The agency reported 2.29 million new cases of chlamydia, gonorrhea and syphilis — three common but treatable STDs — last year, based on preliminary data.

That surpasses the 2016 record by more than 200,000 cases, and marks the fourth consecutive year of increases.

“We are sliding backward,” Jonathan Mermin, director of CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, said in a news release. “It is evident the systems that identify, treat, and ultimately prevent STDs are strained to near-breaking point.”

>> Related: Georgia among worst states for chlamydia, gonorrhea and syphilis rates, CDC report says

Since 2013, gonorrhea diagnoses increased 67 percent overall, with nearly double reported among men and sharp increases reported among women.

Gay, bisexual and other men who have sex with men accounted for 70 percent of the 30,644 cases of primary and secondary syphilis, which increased 76 percent since 2013.

More than 1.7 million chlamydia cases were reported in 2017, 45 percent of which were among 15- to 24-year-old females.

>> Related: Untreatable super-gonorrhea spreading orally, WHO warns

Last year, Georgia ranked among the top five states in America with the highest rates of chlamydia, gonorrhea and syphilis, according to a CDC report.

All three diseases are treatable via antibiotics, but many cases go untreated, “which can lead to severe adverse health effects that include infertility, ectopic pregnancy, stillbirth in infants, and increased HIV risk,”
according to the CDC.

Previous research also suggests socioeconomic factors, stigma, discrimination and drug use may contribute to STD increases.

>> Related: CDC: Please don’t wash or reuse your condoms

In the Aug. 28 announcement, the CDC also addressed concerns about antibiotic resistant gonorrhea.

For now, the agency recommends a two-drug combination to preserve the last highly effective antibiotic: a single shot of ceftriaxone plus an oral dose of azithromycin. But lab tests show there may be rising resistance to azithromycin. There may also ultimately be a strain that will no longer respond to ceftriaxone.

>> Related: The Silent Epidemic: Counting the cost of being ignored
“We expect gonorrhea will eventually wear down our last highly effective antibiotic, and additional treatment options are urgently needed,” Gail Bolan, director of CDC’s Division of STD Prevention, said. “We can’t let our defenses down — we must continue reinforcing efforts to rapidly detect and prevent resistance as long as possible.”

Support real journalism. Support local journalism. Subscribe to The Atlanta Journal-Constitution today. See offers.

Your subscription to the Atlanta Journal-Constitution funds in-depth reporting and investigations that keep you informed. Thank you for supporting real journalism.

X